Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival

Recent Boosts Also Include EIR For Nagpur Plant As Well As US Lurasidone Launch

Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.

Newton's Cradle with red ball
Action on Lupin’s Spiriva generic is expected to add to US momentum • Source: Shutterstock

Lupin has offered an update on expected US Food and Drug Administration action on its proposed Spiriva (tiotropium) generic as it reported results for its financial third quarter that reflected both turnover growth and increased profitability.

The firm now expects FDA action on its tiotropium filing in either April or July, depending on whether the agency...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business